Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | IL6ST | P40189 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27967864 | 1.00 | NAAA (0.46) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL12973848 | 1.00 | NAAA (0.46) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL27967862 | 1.00 | NAAA (0.46) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL2908040 | 0.93 | NAAA (0.43) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL28883791 | 0.92 | SLC18A3 (0.44) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL3493992 | 0.92 | SLC18A3 (0.44) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL542243 | 0.92 | SLC18A3 (0.44) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL2050725 | 0.92 | SLC18A3 (0.44) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL514845 | 0.92 | SLC18A3 (0.44) | NAAANPC1LMNATP53HPGD | |
| SCHEMBL515189 | 0.92 | SLC18A3 (0.44) | NAAANPC1LMNATP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786103-B2 | Method for isolating an intestinal cholesterol binding protein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7671047-B2 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-7435727-B2 | Method for isolating an intestinal cholesterol binding protein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| US-20080167451-A1 | METHOD FOR ISOLATING AN INTESTINAL CHOLESTEROL BINDING PROTEIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1529061-B1 | METHOD FOR ISOLATING AN INTESTINAL CHOLESTEROL BINDING PROTEIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1345932-B1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-10-18 | — | — | EP | disclosed |
| EP-1529061-A1 | METHOD FOR ISOLATING AN INTESTINAL CHOLESTEROL BINDING PROTEIN | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040126812-A1 | Method for isolating an intestinal cholesterol binding protein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20040077623-A1 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004014947-A1 | METHOD FOR ISOLATING AN INTESTINAL CHOLESTEROL BINDING PROTEIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1345932-A1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-6498156-B2 | TREATING HYPERLIPIDEMIA, ARTERIOSCLEROSIS AND HYPERCHOLESTEROLEMIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-24 | — | — | US | disclosed |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
| WO-2002050068-A1 | DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040126812-A1 | Method for isolating an intestinal cholesterol binding protein | FABP2, CETP, HDLBP | NAAA 2652/4885NPC1 9/4885LMNA 2646/4885 |
| US-20040077623-A1 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, DRD4, CYP2D6 | NAAA 3306/4885NPC1 154/4885LMNA 1080/4885 |
| US-20080167451-A1 | METHOD FOR ISOLATING AN INTESTINAL CHOLESTEROL BINDING PROTEIN | FABP2, CETP, HDLBP | NAAA 2814/4885NPC1 13/4885LMNA 2955/4885 |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | NAAA 3924/4885NPC1 140/4885LMNA 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.